Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 27, 2015 8:36 PM ET

Healthcare Equipment and Supplies

Company Overview of Cognoptix, Inc.

Company Overview

Cognoptix, Inc. operates as a medical technology company that creates and develops a non-invasive eye scanning test for the early detection and diagnosis of Alzheimer’s disease. It also develops combined optical scanning devices and diagnostic agents for clinical, commercial, and academic research use. Cognoptix, Inc. was formerly known as Neuroptix Corporation and changed its name to Cognoptix, Inc. in October 2012. The company was founded in 2001 and is based in Acton, Massachusetts.

20 Main Street

Acton, MA 01720

United States

Founded in 2001





Key Executives for Cognoptix, Inc.

Chairman of the Board, Chief Executive Officer and President
Chief Financial Officer
Director of Marketing & Clinical Strategy
Compensation as of Fiscal Year 2014.

Cognoptix, Inc. Key Developments

Cognoptix Appoints Barry D. Greenberg to Clinical Advisory Board

Cognoptix announced that it has appointed Barry D. Greenberg, Ph.D., to its clinical advisory board. Dr. Greenberg is Director of Neuroscience Drug Discovery & Development at University Health Network, Toronto; and, Director of Strategy, Toronto Dementia Research Alliance. Expansion of the Cognoptix Clinical Advisory board follows an announcement by the company on Sept. 30, 2014, that it has closed the first tranche of a Series D round of financing totaling over $15 million.

Cognoptix Announces Board Appointments

Cognoptix announced that it has elected its President and CEO, Paul D. Hartung, as Chairman of the Board. The company also announced that it has elected a new director: Christine de los Reyes, PharmD, Vice President, Business Development and Strategic Planning, Alopexx Enterprises LLC. Dr. Christine de los Reyes is Vice President of Business Development and Strategic Planning at Alopexx Enterprises. Most recently, she was founder and Managing Director of BiotechPartnering Solutions.

Cognoptix, Inc. Presents at 9th Annual The Neurotech Investing & Partnering Conference 2014, Apr-23-2014 10:30 AM

Cognoptix, Inc. Presents at 9th Annual The Neurotech Investing & Partnering Conference 2014, Apr-23-2014 10:30 AM. Venue: The Ritz Carlton, 10 Avery St., Boston, Massachusetts, United States. Speakers: Paul Hartung, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Galaxy Medical Products, Inc. United States
Cardiac Concepts, Inc. United States
Kalila Medical, Inc. United States
PlasmaSol Corporation United States
Bacou USA Safety, Inc. United States

Recent Private Companies Transactions

Private Placement
September 19, 2014
Private Placement
April 15, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cognoptix, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at